P3 Health Partners just delivered one of the most violent single-day moves in the small-cap healthcare space this year. The stock closed May 15 at $11.29 — up 218% on the week and 368% over the past month — after a Q1 2026 earnings release on May 14 sent shares surging 216% in a single session. The stock was halted multiple times on circuit breakers to the upside before resuming trade. What makes the setup worth watching now is what happens in the aftermath: short sellers are quietly rebuilding positions even as the price holds its explosive gains.
The positioning picture is more complex than a simple squeeze narrative. Short interest has climbed from 4.4% of the free float a week ago to 5.2% now — a 21% increase in one week — suggesting fresh shorts are moving in as the stock holds near post-earnings highs. That's notable because earlier in the cycle, shorts had been covering: SI % FF fell from a local peak of around 6.5% in mid-April all the way to 4.3% by early May, likely as bears gave up ahead of the print. Post-earnings, the rebuild is well underway. Cost to borrow, at 7.4%, has actually eased about 10% over the past week as availability remains ample at roughly 447% of short interest — far from a tight borrow market. The ORTEX short score has risen consistently this week, reaching 47.1 on May 14 versus 43.1 a week earlier. That's a mid-range reading in absolute terms, but the direction of travel is firmly upward.
The Street scrambled to catch up following the earnings pop. Lake Street's Ben Haynor — the stock's most active analyst coverage — raised his price target to $14 on May 15, more than tripling his prior $4 target while keeping a Buy rating. That's a meaningful signal from the only bullish voice in a sparse coverage universe. TD Cowen carries a Hold with a $3 target, set in early April before the earnings catalyst. The $3 mean price target in the snapshot reflects those stale pre-print estimates; the actual post-earnings setup is better described by Lake Street's revised $14, which still sits above the current $11.29 close. The 8-K filed simultaneously with the earnings release disclosed a notice of delisting or failure to satisfy a Nasdaq continued listing rule — a detail that could weigh on investor confidence even as the fundamental print drove the rally.
Ownership concentration is extreme and worth flagging. Chicago Pacific Founders holds roughly 42% of shares, and Leavitt Equity Partners controls another 11%. With under 25 institutional holders on record, the float is thin and liquidity is structurally constrained. That dynamic amplifies both the upside volatility seen this week and the risk of sharp reversals. The insider log shows Chicago Pacific Founders buying steadily in September 2024 at prices near $0.50 per share — a very different cost basis from today's $11.29. The most recent insider data is now over 18 months old, so no current read is available on whether insiders are sellers into this week's spike.
The earnings history carries one additional data point of note. The Q1 2025 earnings release in late March 2026 triggered a 6% one-day gain but a 10% loss over the following five days — a pattern of fade after initial enthusiasm. The Q1 2026 print dwarfs that move in magnitude. The next scheduled earnings event is June 9, 2026, which arrives quickly in the context of a stock that has just moved this far this fast. That proximity, the delisting notice, the thin institutional base, and the ongoing short rebuild make the weeks ahead a rich test of whether the underlying business improvement that drove the May 14 earnings reaction can be sustained.
See the live data behind this article on ORTEX.
Open PIII on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
